Clinical Trial Update: Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the effect of gefapixant (MK-7264) on cough reflex sensitivity in refractory chronic cough has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• Gefapixant (gefapixant)

Snippet

Sponsor: Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Refractory Chronic Cough | Phase 2 | Status: COMPLETED | Results posted: 2021-02-12